Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02007577 · ClinicalTrials.gov registry record · NA

Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?

A NA study of PreDiabetes and Insulin Resistant, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
41
Enrollment target
1
Study location

NCT02007577: Completed NA study of PreDiabetes and Insulin Resistant, sponsored by Stanford University.

NCT02007577 is a NA study of PreDiabetes and Insulin Resistant that has completed, run by Stanford University. The registered enrollment target is 41 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02007577, a NA study of PreDiabetes and Insulin Resistant, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

The possibility that obesity-associated inflammatory changes may play a role in the pathogenesis of type 2 diabetes (2DM) has led to increased interest in the possibility that salicylates might represent a useful treatment to improve glucose tolerance. Several studies, performed in patients with 2DM, as well as in nondiabetic, obese individuals, have demonstrated that salicylates have beneficial effects on glucose and insulin metabolism, but have not led to a coherent view as to the mechanism(s) involved. In this research proposal we will use specific methods to quantify insulin mediated glucose uptake (IMGU), glucose-stimulated insulin secretion rate (GS-ISR), and insulin clearance (I-Cl) in overweight/obese, nondiabetic, insulin resistant individuals. We will use the insulin suppression test (IST) to quantify IMGU in nondiabetic, overweight/obese volunteers to identify those individuals who are sufficiently insulin resistant to be enrolled in this study. We will then use the graded glucose infusion technique in these insulin resistant subjects to generate specific measures of both GS-IS and I-Cl. Following these baseline measurements, salsalate or placebo will be administered for one month to the participants, after which time the IST and the graded glucose infusion will be repeated to quantify and compare the changes in IMGU, GS-ISR, and I-Cl that have resulted from salsalate versus placebo. These results will provide for the first time quantitative data of the effect of salicylates on IMGU, GS-ISR, and I-Cl in overweight/obese, insulin resistant, nondiabetic individuals.

Primary Outcome

Compare changes in insulin sensitivity as assesses by the IST before and after treatment between salsalate and placebo group

Interventions

  • DRUG Placebo
  • DRUG salsalate

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2010-07
Est. Completion 2013-11
Phase NA
Stanford University

1,744 total trials

What the finished NCT02007577 record still lists

NCT02007577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02007577 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02007577 about?

NCT02007577 is a clinical study titled "Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?". The possibility that obesity-associated inflammatory changes may play a role in the pathogenesis of type 2 diabetes (2DM) has led to increased interest in the possibility that salicylates might represent a useful treatment to improve glucose tolerance. Several studies, performed in patients with 2DM...

What is the current status of trial NCT02007577?

This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2010-07. Estimated completion is 2013-11.

What conditions does trial NCT02007577 study?

This clinical trial studies the following conditions: PreDiabetes, Insulin Resistant.

What interventions are being tested in trial NCT02007577?

The interventions under investigation include: Placebo (DRUG), salsalate (DRUG).

Who is sponsoring clinical trial NCT02007577?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02007577 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PreDiabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02007577's enrollment target sits among peer trials

41 107th of 149 higher than 43 of 149 other PreDiabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02007577, the US trial registry maintained by the National Library of Medicine. NCT02007577 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.